FindTrial
Sign In

A Study Comparing Everolimus Stents and Sirolimus Balloons for Treating New Coronary Artery Blockages

DUALITY: A Comparative Outcomes of Everolimus-Eluting Stents versus Sirolimus- Eluting Balloons in Patients with De Novo Coronary Lesions - A Single-Center Ambispective Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/06/111803
Enrollment
176
Registered
2026-06-03
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I259- Chronic ischemic heart disease, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Intervention4: Nil: Nil Intervention5: Nil: Nil Intervention6: Nil: Nil Control Intervention1: NIL: NIL

Sponsors

Anil Neerukonda Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All the Patients who have been treated with Everolimus-Eluting stent or Sirolimus-Eluting Balloon. 2. All patients with de novo small coronary artery vessel disease with diameter more than 2 mm and less than or equal to 3 mm at visual estimation. 3. Participants willing to undergo study-related follow-up requirements.

Exclusion criteria

Exclusion criteria: 1. All the Patients who have not been treated with Everolimus-Eluting stent or Sirolimus-Eluting Balloon. 2. All patients with de novo coronary artery vessel disease with diameter greater than 3.0 mm at visual estimation. 3. Participants not willing to undergo study-related follow-up requirements.

Design outcomes

Primary

MeasureTime frame
1. Major Adverse Cardiac EventsTimepoint: Time Frame: Intra-Procedure, Post Procedure, Discharge, 1 month, 3 months, through 6 months, 12 month 15 days—

Secondary

MeasureTime frame
Target vessel failureTimepoint: Time Frame: Intra-Procedure, Post Procedure, Discharge, 1 month, 3 months, through 6 months, 12 month 15 days;Adverse events/ Serious Adverse EventsTimepoint: Time Frame: Intra-Procedure, Post Procedure, Discharge, 1 month, 3 months, through 6 months, 12 month 15 days;Seattle Angina Questionnaire (SAQ)Timepoint: Time Frame: Pre Procedure, 1 month, 3 months, through 6 months, 12 month 15 days;Laboratory Measurements and Non-Invasive TestsTimepoint: Time Frame: Baseline, through 6 months;Procedural SuccessTimepoint: Time frame: Post procedure;Device SuccessTimepoint: Time frame: Intra-procedure—

Countries

India

Contacts

Public ContactPooja Kotla

Anil Neerukonda Hospital

kumar.has.suresh55@gmail.com9866311341

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026